Long-term benefits of Vyepti® confirmed by new data presented at the annual meeting of the American Headache Society

Long-term benefits of Vyepti® confirmed by new data presented at the annual meeting of the American Headache SocietyAn extension phase of the DELIVER study with Vyepti® (eptinezumab) demonstrated long-lasting migraine preventive effects with treatment for up to 18 months, reducing both frequency and severity...

Related Keywords

Valby ,Hovedstaden ,Denmark ,Texas ,United States ,American ,Johan Luthman ,Thomas Mikkel Mortensen ,Palle Holm Olesen ,European Medicines Agency ,Drug Administration ,Harris Poll Migraine Report Card ,Linkedin ,American Headache Society ,Lundbeck ,Scientific Meeting Of The American Headache Society ,Head Of Research Development At Lundbeck ,American Headache ,Annual Scientific Meeting ,Scientific Meeting ,Relations Lead ,Headache Impact ,Work Productivity ,Activity Impairment Questionnaire ,Global Burden ,